Temple-backed biotech inches closer to potential HIV cure with key move by FDA


Using the CRISPR genome-editing technology that won a share of the 2020 Nobel Prize in chemistry, the company has a potential cure for HIV in an early-stage clinical trial.

Previous Guest notebook: Alzheimer's Association demands access to FDA-approved treatments
Next After stint at CVS, UnitedHealth vet Dr. Amar Desai returns to lead Optum Health